Rebates reduced the growth in Medicare Part D spending for brand-name drugs between 2011 and 2015, but spending for brand-name drugs with rebates still grew by $2 billion over the five-year period, according to a report released last week by the Department of Health and Human Services’ Office of Inspector General. Without rebates, total Part D reimbursement for brand-name drugs would have risen 19% over the period, OIG found. In response to a congressional request, OIG examined 1,510 brand-name drugs with Part D reimbursement and rebates each year over the period.

Headline
The American Medical Association Nov. 17 released its latest annual report on health insurance competition, which found that 95% of commercial markets were…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $40 in calendar year 2026 to $1,776, the Centers for Medicare & Medicaid…
Headline
The Centers for Medicare & Medicaid Services Nov. 16 issued a proposed rule on program integrity oversight in Medicare, Medicaid, the Children’s Health…
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…